Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:19303543rdf:typepubmed:Citationlld:pubmed
pubmed-article:19303543lifeskim:mentionsumls-concept:C0022104lld:lifeskim
pubmed-article:19303543lifeskim:mentionsumls-concept:C1274040lld:lifeskim
pubmed-article:19303543lifeskim:mentionsumls-concept:C1879746lld:lifeskim
pubmed-article:19303543lifeskim:mentionsumls-concept:C1547011lld:lifeskim
pubmed-article:19303543pubmed:dateCreated2009-3-23lld:pubmed
pubmed-article:19303543pubmed:abstractTextIrritable bowel syndrome is a chronic relapsing disorder. In most patients, symptom severity and clinical characteristics change frequently. Nonetheless, broad progressive trends can be defined. Over the very short term, symptoms occur over short sequences appearing sequentially and are interrupted by short remission periods. Over the medium term (3 months), early recovery from symptoms is observed in 20%-40% of patients. No good clinical predictors of IBS progression seem to exist even if clinical improvement at 3 months seems related to a better prognosis after a 1-year follow-up. Over the long term (several years), symptoms are still present in 60%-70% of patients. Symptom turnover is high in these patients from either transitioning into other irritable bowel syndrome subgroups or overlapping with dyspeptic symptoms. Psychiatric comorbidities appear to be of primary importance in the clinical course of patients with irritable bowel syndrome.lld:pubmed
pubmed-article:19303543pubmed:languagefrelld:pubmed
pubmed-article:19303543pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19303543pubmed:citationSubsetIMlld:pubmed
pubmed-article:19303543pubmed:statusMEDLINElld:pubmed
pubmed-article:19303543pubmed:monthFeblld:pubmed
pubmed-article:19303543pubmed:issn0399-8320lld:pubmed
pubmed-article:19303543pubmed:authorpubmed-author:Bruley des...lld:pubmed
pubmed-article:19303543pubmed:issnTypePrintlld:pubmed
pubmed-article:19303543pubmed:volume33 Suppl 1lld:pubmed
pubmed-article:19303543pubmed:ownerNLMlld:pubmed
pubmed-article:19303543pubmed:authorsCompleteYlld:pubmed
pubmed-article:19303543pubmed:paginationS84-90lld:pubmed
pubmed-article:19303543pubmed:dateRevised2010-8-17lld:pubmed
pubmed-article:19303543pubmed:meshHeadingpubmed-meshheading:19303543...lld:pubmed
pubmed-article:19303543pubmed:meshHeadingpubmed-meshheading:19303543...lld:pubmed
pubmed-article:19303543pubmed:meshHeadingpubmed-meshheading:19303543...lld:pubmed
pubmed-article:19303543pubmed:meshHeadingpubmed-meshheading:19303543...lld:pubmed
pubmed-article:19303543pubmed:meshHeadingpubmed-meshheading:19303543...lld:pubmed
pubmed-article:19303543pubmed:year2009lld:pubmed
pubmed-article:19303543pubmed:articleTitle[Irritable bowel syndrome: outcome aspects].lld:pubmed
pubmed-article:19303543pubmed:affiliationInstitut des Maladies de l'Appareil Digestif, CHU Hôtel Dieu, 44093 Nantes cedex, France. stanislab.bruleydesvarannes@chu-nantes.frlld:pubmed
pubmed-article:19303543pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:19303543pubmed:publicationTypeEnglish Abstractlld:pubmed